BSE: LAURUSLABS - Laurus Labs Limited

Доходность за полгода: +12.03%

График акции Laurus Labs Limited


О компании

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs.

Подробнее
In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

P/E 15.89
P/S 1.4328
P/BV 2.29
EV/EBITDA 9.22
EBITDA 5.54
Цена ао 470.2
Дивиденд ао 2
Див.доход ао 0.57
Сайт https://www.lauruslabs.com
Выручка 28.32
Число акций ао 0.53897 млрд
Валюта inr
ISIN INE947Q01028
Sector Health Care
Industry Pharmaceuticals
Валюта отчета inr
Изменение цены за день: +0.4102% (463.2)
Изменение цены за неделю: -0.4708% (467.3)
Изменение цены за месяц: +1.6279% (457.65)
Изменение цены за 3 месяца: +9.63% (424.25)
Изменение цены за полгода: +12.03% (415.15)
Изменение цены за год: +17.69% (395.2)
Изменение цены за 3 года: -28.43% (649.85)
Изменение цены за 5 лет: +45.82% (318.95)
Изменение цены с начала года: +8.23% (429.75)

Недооценка

Название Значение Оценка
P/S 4.47 4
P/BV 5.44 2
P/E 139.4 1
EV/EBITDA 14.08 7
Итого: 4.5

Эффективность

Название Значение Оценка
ROA, % 1.9143 1
ROE, % 3.91 1
Итого: 1.8333

Дивиденды

Название Значение Оценка
Div yield, % 0.6439 1.6
DSI 0.8571 8.57
Итого: 3.41

Долг

Название Значение Оценка
Debt/EBITDA 1.261 8
Итого: 7

Импульс роста

Название Значение Оценка
Доходность Revenue, % 76.63 8
Доходность Ebitda, % 188.31 10
Доходность EPS, % -15.58 0
Итого: 3.6

ETF Доля, % Доходность за год, % Дивиденды, %
Avantis Emerging Markets Equity ETF 0.03524 23.84 3.60513
Avantis Emerging Markets Value ETF 0.03274 22.32 4.22231
Dimensional World ex U.S. Core Equity 2 ETF 0.01011 21.13 3.62488
Dimensional Emerging Markets Core Equity 2 ETF 0.07105 21.50 3.34087
WisdomTree Emerging Markets SmallCap Dividend Fund 0.04081 19.00 5.00999
WisdomTree Global ex-U.S. Quality Dividend Growth Fund 0.01699 18.23 2.73928
iShares MSCI Emerging Markets Small-Cap ETF 0.14838 19.45 2.7853
WisdomTree India Earnings Fund 0.11416 37.52 1.65591
Franklin FTSE Asia ex Japan ETF 0.03027 21.51 2.66768
Franklin FTSE India ETF 0.12135 34.68 1.25133
iShares Core MSCI Total International Stock ETF 0.00853 22.38 3.25258
iShares MSCI India Small-Cap ETF 0.47272 38.45 0.96163
SPDR Portfolio Emerging Markets ETF 0.01552 23.97 3.1879
SPDR Portfolio MSCI Global Stock Market ETF 0.01304 29.28 2.19607
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.01631 19.84 3.59676
Vanguard ESG International Stock ETF 0.01 23.48 3.07501

Руководитель Должность Оплата Год рождения
Dr. Satyanarayana Chava M.Sc., Ph.D. CEO & Whole Time Director 186.44M 1961 (63 года)
Mr. Vantaram Venkata Ravi Kumar Dip in Mgmt., DIS, F.C.M.A. CFO & Whole-Time Director 49.65M 1965 (59 лет)
Mr. B. V. R. K. Suryadevara Srinivasa Rao Executive Vice President of Manufacturing & Operations N/A 1968 (56 лет)
Mr. Narasimha Rao Chava Executive Vice President of Human Resources N/A 1968 (56 лет)
Dr. Lakshmana Rao Venkata Chunduru M.Sc., Ph.D. Head of Quality & Executive Director 33M 1962 (62 года)
Mr. Srinivasa Rao Suryadevara B.Sc, M.Sc. Executive Vice President of Manufacturing N/A 1963 (61 год)
Mr. Chagarlamudi Sita Ramaiah Executive Vice President of Finance N/A 1973 (51 год)
Mr. Dammalapati Venkata Lakshmi Narasimha Rao Executive Vice President of Synthesis N/A 1969 (55 лет)
Mr. Krishna Chaitanya Chava Executive VP, Head of Synthesis & Ingredients and Executive Director N/A 1990 (34 года)
Mr. Rajaram Iyer M.B.A. Executive Vice President of Portfolio Management 1974 (50 лет)

Адрес: India, Hyderabad, Serene Chambers - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.lauruslabs.com